TMCnet News
$2.8 Billion Blood Screening Market by Technology, Product & End User - Global Forecasts to 2021 - Research and MarketsResearch and Markets has announced the addition of the "Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User - Global Forecasts to 2021" report to their offering. The market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7%. The major factors driving the growth of this market are increasing number of blood donations and blood donors and rising awareness regarding the safety of donated blood. In addition, increasing affordability and adoption of nucleic acid test (NAT) for blood screening, rising demand for donated blood, and increasing prevalence of infectious diseases are also driving the growth of this market. However, capital expenditure and the operating costs of NAT instruments, lack of mandates for NAT in developing countries, and the emergence of altenative technologies are restraining market growth. Furthermore, some of the major opportunities observed in this market include growing economies such as China and India, the emergence of pathogen reduction technology, and demand of multiplex tests. Market Dynamics Drivers
Restraints
Opportunities
Challenges
Companies Mentioned
For more information about this report visit http://www.researchandmarkets.com/research/f5hjv9/blood_screening
View source version on businesswire.com: http://www.businesswire.com/news/home/20170130005921/en/ |